Fenoldopam monohydrobromide 

Fenoldopam is a selective dopamine agonist that is being considered for the parenteral treatment of systemic hypertension. In both an oral and parenteral form, fenoldopam causes peripheral vasodilation by stimulating dopamine-1 adrenergic receptors. Intravenous fenoldopam may provide advantages over sodium nitroprusside because it can induce both a diuresis and natriuresis, is not light sensitive, and is not associated with cyanide toxicity. There is no evidence for rebound hypertension after discontinuation of fenoldopam infusion.

≥98%

protect from light

under inert gas

off-white

DMSO: >12 mg/mL

H₂O: 4.75 mg/mL

human ... ADRA1A(148), ADRA1B(147), ADRA1D(146), DRD1(1812)

2-8°C

Hahn, R.A., et al., Characterization of the peripheral and central effects of SK&F 82526a novel dopamine receptor agonist. J. Pharmacol. Exp. Ther. 223, 305-313, (1982) abstract

Venkatakrishnan, U., et al., The role of intrarenal nitric oxide in the natriuretic response to dopamine-receptor activation. Clin. Exp. Hypertens. 22, 309-324, (2000) abstract

Quevedo, M., et al., The effect of fenoldopam on the blood pressure of the rat. Gen. Pharmacol. 32, 123-125, (1999) abstract

Hussain, T., and Lokhandwala, M.F., Renal dopamine DA1 receptor coupling with G(S) and G(q/11) proteins in spontaneously hypertensive rats. Am. J. Physiol. 272, F339-F346, (1997) abstract

deVries, P.A., et al., Impaired renal vascular response to a D1-like receptor agonist but not to an ACE inhibitor in conscious spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 34, 191-198, (1999) abstract

Xn

22-36-42/43

22-26-36/37/39

3